Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: LY3437943
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Triple-receptor agonist peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Single GIP/GLP-1/glucagon receptor agonist.
Evidence and critical reading
Reported scientific and empirical uses
Reported glycemic control · Reported weight management
Promoted as a triple agonist for weight; commercial lists are not access to the trial product.
Human evidence
Phase II and 2026 TRIUMPH-2 phase III evidence show weight reduction in studied populations. Investigational status is distinct from efficacy signals.
Preclinical evidence
Receptor balance is molecule-specific and cannot be reproduced by arbitrary stacking.
Critical reading and limitations
Phase II trials and the selected phase III report require population/outcome context; efficacy is not approval.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
1 / 4 / 8 / 12 mg · Target amounts in separate arms
- Frequency
- Weekly
- Duration
- 48 weeks
- Route
- Subcutaneous
- Context
- Phase II, 338 adults; arms used different starting exposures.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID37366315 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
4 / 9 / 12 mg · Target amounts in separate arms
- Frequency
- Weekly
- Duration
- 80 weeks
- Route
- Subcutaneous
- Context
- Phase III, obesity/type 2 diabetes; not a community regimen.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID42810372 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
US: FDA states no approved retatrutide product and restrictions on compounding. EU authorization not verified.
Adverse effects and unknowns
GI adverse effects and heart-rate increases reported; long-term and combination safety remain under study. Trial exclusions are not approved-label contraindications.
GI events and heart-rate changes in research; mixtures lack established equivalence.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID37366315 · Randomized controlled trial
Adults with overweight/obesity.
Weekly SC, 48 weeks.
Phase II: 12-mg arm −24.2% versus −2.1%; GI effects/heart-rate changes.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 338
PMID42810372 · Randomized controlled trial
Obesity/type 2 diabetes.
Weekly SC, 80 weeks.
Phase III, regimen estimand: 12 mg −18.8% versus −5.1%.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 1152
Trials attributed in the package
NCT04881760 · A Study of LY3437943 in Participants Who Have Obesity or Are OverweightRegistry status: CompletedLast update posted: September 13, 2023Query verification: October 16, 2026
NCT05929079 · A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightRegistry status: CompletedLast update posted: July 30, 2026Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Retatrutide · 33 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07165028 · A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Registry status: RecruitingLast update posted: October 8, 2026Query verification: October 16, 2026
NCT06383390 · The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Registry status: Active, not recruitingLast update posted: October 8, 2026Query verification: October 16, 2026
NCT06982859 · A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusRegistry status: Active, not recruitingLast update posted: October 6, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID37366315
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, Retatrutide Phase 2 Obesity Trial Investigators.
October 16, 2026
- PMID42810372
Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A.
October 16, 2026
- R28
- R29
- R30
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026